scholarly journals Peer Support and Psychosocial Pain Management Strategies for Children with Systemic Lupus Erythematosus

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Laura Nabors ◽  
Teminijesu John Ige ◽  
Bradley Fevrier
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Pain Management ◽  
Peer Support ◽  
Lupus Erythematosus ◽  
Management Strategies ◽  
Children And Families ◽  
Psychological Pain ◽  
Systemic Lupus ◽  
New Information ◽  
Psychological Pain Management

This paper reviews information on Systemic Lupus Erythematosus (SLE) in children. Children with this chronic illness often experience pain related to their condition. They also can experience social isolation. This paper reviews psychosocial information on peer support and cognitive behavioral pain management strategies. The information presented in this paper provides new insights for health professionals assisting children and families in coping with psychological facets of this disease. Research focusing on ways by which peers and friends can support the child’s use of psychological pain management strategies will provide new information for the literature.

Unconventional Pain Management for People With Systemic Lupus Erythematosus: A Systematic Literature Review

2020 ◽  
Vol 51 (1) ◽  
pp. 3-15
Author(s):  
Viviana Garza
Keyword(s):  
Quality Of Life ◽  
Systemic Lupus Erythematosus ◽  
Chronic Pain ◽  
Pain Management ◽  
Mental Health Professionals ◽  
Lupus Erythematosus ◽  
Expressive Writing ◽  
Treatment Plan ◽  
Systemic Lupus

People with chronic pain account for 65% of the population diagnosed with systemic lupus erythematosus (SLE). SLE is a fast-growing medical autoimmune disease responsible for 16,000 new cases yearly. More than 60% experience chronic pain due to arthritis related conditions causing daily distress and an overall diminished quality of life. Methods of pain management have helped relieve the psychosocial and physical effects pain causes on individuals. The purpose of this review was to explore methods of pain interventions used among people with SLE. A systematic literature search was conducted to examine methods of pain management among people with SLE. Seven articles met the inclusion and exclusion criteria. Findings suggest that pain management methods such as cognitive behavior therapy, education interventions, physical exercise, expressive writing, benefit finding writing, and acupuncture have been helpful in pain management among people with SLE. Benefits of utilizing these pain management methods include improved physical activity, social function, pain reduction, better sleep, and improved overall quality of life. Health and mental health professionals can consider these methods when developing a comprehensive pain treatment plan for people with SLE.

Hematological features of pediatric systemic lupus erythematosus: suggesting management strategies in children

Lupus ◽  
2012 ◽  
Vol 21 (8) ◽  
pp. 878-884 ◽  
Author(s):  
M Gokce ◽  
Y Bilginer ◽  
N Besbas ◽  
F Ozaltın ◽  
M Cetin ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Management Strategies ◽  
Systemic Lupus ◽  
Pediatric Systemic Lupus Erythematosus

scholarly journals Biomarkers Associated with Organ-Specific Involvement in Juvenile Systemic Lupus Erythematosus

2021 ◽  
Vol 22 (14) ◽  
pp. 7619
Author(s):  
James Greenan-Barrett ◽  
Georgia Doolan ◽  
Devina Shah ◽  
Simrun Virdee ◽  
George A. Robinson ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Severe Disease ◽  
Management Strategies ◽  
Joint Disease ◽  
Adult Onset ◽  
Systemic Lupus ◽  
Juvenile Systemic Lupus Erythematosus ◽  
Organ Specific ◽  
Specific Organ

Juvenile systemic lupus erythematosus (JSLE) is characterised by onset before 18 years of age and more severe disease phenotype, increased morbidity and mortality compared to adult-onset SLE. Management strategies in JSLE rely heavily on evidence derived from adult-onset SLE studies; therefore, identifying biomarkers associated with the disease pathogenesis and reflecting particularities of JSLE clinical phenotype holds promise for better patient management and improved outcomes. This narrative review summarises the evidence related to various traditional and novel biomarkers that have shown a promising role in identifying and predicting specific organ involvement in JSLE and appraises the evidence regarding their clinical utility, focusing in particular on renal biomarkers, while also emphasising the research into cardiovascular, haematological, neurological, skin and joint disease-related JSLE biomarkers, as well as genetic biomarkers with potential clinical applications.

scholarly journals Hematological Disorders in Patients with Systemic Lupus Erythematosus

2013 ◽  
Vol 7 (1) ◽  
pp. 87-95 ◽  
Author(s):  
Fozya Bashal
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Management Strategies ◽  
Immunosuppressive Drugs ◽  
Systemic Lupus ◽  
Acute Exacerbations ◽  
Diagnostic Approaches ◽  
Hematological Abnormalities ◽  
High Doses ◽  
Hematological Manifestations

This article is a review of different management strategies for the hematological manifestations of systemic lupus erythematosus (SLE), the strategies include immunosuppressive drugs, some noval therapies and B-cell depletion for refractory thrombocytopenia in patients with SLE and in antiphospholipid antibody syndrome associated with SLE. The researcher questions the validity of the current classic treatment modes and the article explores the relationships between SLE hematological manifestations and the level of morbidity and mortality burden and focuses on the pathophysiology, diagnostic approaches and management strategies of these manifestations. The researcher focuses on hematological abnormalities because they are the commonest among most manifestations in SLE seen in Anemia, leucopenias and thrombocytopenia. They commonly result from an immune mediated bone marrow failure, excessive peripheral cells destruction or certain drugs and infections. There is also an association between anti-phospholipid antibody syndrome (APS) and SLE referred to as secondary APS or SLE-APS. Furthermore, it was recently found that mycophenolatemofetil acts as corticosteroids and as cyclophosphamide sparing agent. Although there is no specific therapy for cytopenias in SLE, corticosteroids remain the mainstay in the treatment of these patients along with less used other conventional treatment options such as azathioprine, cyclophosphamide and human normal immunoglobulin. There are other novel therapies such as thrombopoietin receptor agonists in thrombocytopenia and the use of autologous hematopoitic stem cells transplantation in refractory SLE-APS that are under review. Some of these therapies include thrombopoietin receptor agonists in thrombocytopenia and the use of autologous hematopoitic stem cells transplantation in refractory SLE-APS. The study concludes that treatment of hematological abnormalities is challenging because the treatment itself can cause undue complications sometimes such as granulocytosis due to infection or the use of high doses of steroids and may occur during acute exacerbations of SLE. It is important to take these factors into consideration for disease therapy and management. Publication Abstract: This article is a review of different management strategies for the hematological manifestations of systemic lupus erythematosus (SLE). The strategies include immunosuppressive drugs, some novel therapies and B-cell depletion for refractory thrombocytopenia in patients with SLE and in anti-phospholipid antibody syndrome associated with SLE. The researcher questions the validity of the current classic treatment modes and the article explores the relationships between SLE hematological manifestations and the level of morbidity and mortality burden while it focuses on the pathophysiology, diagnostic approaches and management strategies. The study concludes that hematological abnormalities are the commonest among most manifestations in SLE, and that their treatment is challenging because the treatment itself can cause undue complications sometimes such as granulocytosis due to infection or the use of high doses of steroids and may occur during acute exacerbations of SLE. It is important to take these factors into consideration for disease therapy and management.

Organized Intraglomerular Deposits in NZB Mouse Disease

1971 ◽  
Vol 29 ◽  
pp. 544-545
Author(s):  
Francis R. Comerford ◽  
Alan S. Cohen
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antinuclear Antibodies ◽  
Human Systemic Lupus Erythematosus ◽  
Systemic Lupus ◽  
Glomerular Lesion ◽  
Ultrastructural Studies ◽  
Dense Deposits ◽  
Experimental Nephritis ◽  
Glomerular Lesions

Mice of the inbred NZB strain develop a spontaneous disease characterized by autoimmune hemolytic anemia, positive lupus erythematosus cell tests and antinuclear antibodies and nephritis. This disease is analogous to human systemic lupus erythematosus. In ultrastructural studies of the glomerular lesion in NZB mice, intraglomerular dense deposits in mesangial, subepithelial and subendothelial locations were described. In common with the findings in many examples of human and experimental nephritis, including many cases of human lupus nephritis, these deposits were amorphous or slightly granular in appearance with no definable substructure.We have recently observed structured deposits in the glomeruli of NZB mice. They were uncommon and were found in older animals with severe glomerular lesions by morphologic criteria. They were seen most commonly as extracellular elements in subendothelial and mesangial regions. The deposits ranged up to 3 microns in greatest dimension and were often adjacent to deposits of lipid-like round particles of 30 to 250 millimicrons in diameter and with amorphous dense deposits.

“Subcortical” cognitive impairment in patients with systemic lupus erythematosus

2000 ◽  
Vol 6 (7) ◽  
pp. 821-825 ◽  
Author(s):  
ELIZABETH LERITZ ◽  
JASON BRANDT ◽  
MELISSA MINOR ◽  
FRANCES REIS-JENSEN ◽  
MICHELLE PETRI
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Cognitive Impairment ◽  
Lupus Erythematosus ◽  
Systemic Lupus
Sign in / Sign up

Export Citation Format

Share Document